TRDA
Entrada Announces Positive Phase 1/2 DMD Data
Entrada Therapeutics announces Cohort 1 of the ELEVATE-45-201 study met primary objectives with favorable safety and a statistically significant mean increase in dystrophin production.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.